Wed, October 11, 2017
Tue, October 10, 2017
Mon, October 9, 2017
Fri, October 6, 2017
Thu, October 5, 2017
Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017

Matthew Harrison Upgraded (SRPT) to Buy on, Oct 2nd, 2017


//stocks-investing.news-articles.net/content/201 .. rrison-upgraded-srpt-to-buy-on-oct-2nd-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Harrison of Morgan Stanley, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, Oct 2nd, 2017.

Matthew has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Initiated at Hold and Held Target at $46 on, Thursday, September 7th, 2017


This is the rating of the analyst that currently disagrees with Matthew


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017

Publication Contributing Sources